{"id":"NCT00675792","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)","officialTitle":"A Multi-center, Randomized, Parallel Group, Comparative, Active Controlled, Safety-assessor Blinded, Anesthesiologist-TOF-Watch® SX Blinded Trial Comparing T4/T1 Ratio at Time of Tracheal Extubation Using 4 mg/kg Sugammadex Administered at 1-2 PTCs or Better After the Last Dose of Rocuronium Bromide to 50 µg/kg Neostigmine Administered as Per Standard of Care in Adult Subjects Undergoing Elective Open Abdominal Procedures Requiring Neuromuscular Blockade Reversal","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2008-09","completion":"2008-09","firstPosted":"2008-05-12","resultsPosted":"2013-07-11","lastUpdate":"2015-03-13"},"enrollment":100,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Anesthesia"],"interventions":[{"type":"DRUG","name":"Sugammadex","otherNames":["Org 25969","SCH 900616","MK-8616","Bridion®"]},{"type":"DRUG","name":"Neostigmine","otherNames":["Prostigmin®"]},{"type":"DRUG","name":"Rocuronium","otherNames":["Rocuronium bromide","Esmeron®"]}],"arms":[{"label":"Sugammadex","type":"EXPERIMENTAL"},{"label":"Neostigmine","type":"ACTIVE_COMPARATOR"}],"summary":"The primary purpose of this study is to compare the incidence of\n\nresidual neuromuscular blockade at the time of tracheal extubation after reversal of rocuronium bromide-induced neuromuscular blockade by 4 mg/kg sugammadex with that of 50 µg/kg neostigmine. Residual neuromuscular blockade is defined as the fourth twitch to first twitch (T4/T1) ratio of\n\n\\< 0.90.","primaryOutcome":{"measure":"Residual Neuromuscular Blockade Evidenced by T4/T1 Ratio at the Time of Tracheal Extubation","timeFrame":"Up to the first 24 hours after tracheal extubation","effectByArm":[{"arm":"Sugammadex","deltaMin":1.02,"sd":0.15},{"arm":"Neostigmine","deltaMin":0.78,"sd":0.24}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":51},"commonTop":["Procedural pain","Nausea","Vomiting","Incision site pain","Constipation"]}}